# Prestige Consumer Healthcare Inc. (PBH)

Informational only - not investment advice.

CIK: 0001295947
SIC: 2834 Pharmaceutical Preparations
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2834 Pharmaceutical Preparations](/industry/2834/)
Latest 10-K filed: 2026-05-14
SEC page: https://www.sec.gov/edgar/browse/?CIK=1295947
Filing source: https://www.sec.gov/Archives/edgar/data/1295947/000129594726000016/pbh-20260331.htm

## At a glance

FY2026 · period end 2026-03-31 · filed 2026-05-14 · accession 0001295947-26-000016 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001295947.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 1,088,705,000 USD | 2026 | verified |
| Net income | 190,301,000 USD | 2026 | verified |
| Assets | 3,494,313,000 USD | 2026 | verified |
| Free cash flow | 246,449,000 USD | 2026 | computed |
| Net margin | 17.48% | 2026 | computed |
| Operating margin | 28.42% | 2026 | computed |
| Revenue YoY | -4.31% | 2026 | computed |
| ROE | 10.08% | 2026 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2026 revenue ÷ FY2025 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | PBH | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 17.5% | 1.0% | 75 | 107 |
| Operating margin | 28.4% | -1.3% | 89 | 100 |
| Revenue growth | -4.3% | 14.7% | 19 | 127 |
| FCF margin | 22.6% | -14.0% | 82 | 127 |
| ROE | 10.1% | -30.7% | 77 | 171 |
| ROA | 5.4% | -21.8% | 80 | 187 |
| Liabilities / equity | 0.85 | 0.38 | 65 | 173 |
| Current ratio | 3.57 | 4.89 | 37 | 188 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2834 Pharmaceutical Preparations, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 1088705000 | USD | 2026 | 2026-05-14 |
| Net income | 190301000 | USD | 2026 | 2026-05-14 |
| Assets | 3494313000 | USD | 2026 | 2026-05-14 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-05-14. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001295947.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 882,060,000 | 1,041,179,000 | 975,777,000 | 963,010,000 | 943,365,000 | 1,086,812,000 | 1,127,725,000 | 1,125,357,000 | 1,137,762,000 | 1,088,705,000 |
| Net income | 69,395,000 | 339,570,000 | -35,800,000 | 142,281,000 | 164,682,000 | 205,381,000 | -82,306,000 | 209,339,000 | 214,605,000 | 190,301,000 |
| Operating income | 205,643,000 | 215,474,000 | 67,503,000 | 291,155,000 | 297,402,000 | 329,919,000 | -22,415,000 | 342,429,000 | 336,775,000 | 309,409,000 |
| Gross profit | 500,286,000 | 576,505,000 | 555,576,000 | 552,223,000 | 547,472,000 | 620,646,000 | 625,294,000 | 624,448,000 | 634,463,000 | 595,578,000 |
| Diluted EPS | 1.30 | 6.34 | -0.69 | 2.78 | 3.25 | 4.04 | -1.65 | 4.17 | 4.29 | 3.91 |
| Operating cash flow | 148,672,000 | 210,110,000 | 189,284,000 | 217,124,000 | 235,607,000 | 259,922,000 | 229,716,000 | 248,926,000 | 251,515,000 | 257,627,000 |
| Capital expenditures | 2,977,000 | 12,532,000 | 10,480,000 | 14,560,000 | 22,243,000 | 9,642,000 | 7,784,000 | 9,550,000 | 8,224,000 | 11,178,000 |
| Share buybacks | 0.00 | 0.00 | 49,978,000 | 56,721,000 | 11,867,000 | 0.00 | 50,000,000 | 25,000,000 | 51,509,000 | 156,283,000 |
| Assets | 3,911,348,000 | 3,760,612,000 | 3,441,036,000 | 3,513,905,000 | 3,429,273,000 | 3,670,681,000 | 3,353,729,000 | 3,318,417,000 | 3,402,218,000 | 3,494,313,000 |
| Liabilities | 3,088,799,000 | 2,582,002,000 | 2,345,205,000 | 2,342,934,000 | 2,070,975,000 | 2,093,070,000 | 1,906,645,000 | 1,663,333,000 | 1,567,321,000 | 1,606,797,000 |
| Stockholders' equity | 822,549,000 | 1,178,610,000 | 1,095,831,000 | 1,170,971,000 | 1,358,298,000 | 1,577,611,000 | 1,447,084,000 | 1,655,084,000 | 1,834,897,000 | 1,887,516,000 |
| Cash and cash equivalents | 41,855,000 | 32,548,000 | 27,530,000 | 94,760,000 | 32,302,000 | 27,185,000 | 58,489,000 | 46,469,000 | 97,884,000 | 63,868,000 |
| Free cash flow | 145,695,000 | 197,578,000 | 178,804,000 | 202,564,000 | 213,364,000 | 250,280,000 | 221,932,000 | 239,376,000 | 243,291,000 | 246,449,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | 7.87% | 32.61% | -3.67% | 14.77% | 17.46% | 18.90% | -7.30% | 18.60% | 18.86% | 17.48% |
| Operating margin | 23.31% | 20.70% | 6.92% | 30.23% | 31.53% | 30.36% | -1.99% | 30.43% | 29.60% | 28.42% |
| Return on equity | 8.44% | 28.81% | -3.27% | 12.15% | 12.12% | 13.02% | -5.69% | 12.65% | 11.70% | 10.08% |
| Return on assets | 1.77% | 9.03% | -1.04% | 4.05% | 4.80% | 5.60% | -2.45% | 6.31% | 6.31% | 5.45% |
| Liabilities / equity | 3.76 | 2.19 | 2.14 | 2.00 | 1.52 | 1.33 | 1.32 | 1.00 | 0.85 | 0.85 |
| Current ratio | 2.06 | 2.46 | 2.37 | 2.44 | 2.21 | 2.04 | 2.44 | 3.20 | 4.20 | 3.57 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001295947.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2023-Q2 | 2022-09-30 |  |  | 1.02 | reported discrete quarter |
| 2023-Q3 | 2022-12-31 |  |  | 1.04 | reported discrete quarter |
| 2024-Q1 | 2023-06-30 |  |  | 1.06 | reported discrete quarter |
| 2024-Q2 | 2023-09-30 | 286,316,000 | 53,559,000 | 1.07 | reported discrete quarter |
| 2024-Q3 | 2023-12-31 | 282,741,000 | 53,046,000 | 1.06 | reported discrete quarter |
| 2024-Q4 | 2024-03-31 | 276,991,000 | 49,458,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2024-06-30 | 267,142,000 | 49,068,000 | 0.98 | reported discrete quarter |
| 2025-Q2 | 2024-09-30 | 283,785,000 | 54,377,000 | 1.09 | reported discrete quarter |
| 2025-Q3 | 2024-12-31 | 290,317,000 | 61,032,000 | 1.22 | reported discrete quarter |
| 2025-Q4 | 2025-03-31 | 296,518,000 | 50,128,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2025-06-30 | 249,530,000 | 47,466,000 | 0.95 | reported discrete quarter |
| 2026-Q2 | 2025-09-30 | 274,114,000 | 42,211,000 | 0.86 | reported discrete quarter |
| 2026-Q3 | 2025-12-31 | 283,444,000 | 46,696,000 | 0.97 | reported discrete quarter |
| 2026-Q4 | 2026-03-31 | 281,617,000 | 53,928,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2027-Q1 | 2026-06-30 | 265,710,000 | 29,177,000 | 0.61 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from PBH's latest 10-K: [/company/PBH/business/](/company/PBH/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from PBH's latest 10-K: [/company/PBH/risk-factors/](/company/PBH/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1295947/000129594726000042/pbh-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-06
Report date: 2026-06-30

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with the Condensed Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2026.  This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties.  Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and in future reports filed with the U.S. Securities and Exchange Commission ("SEC").

See also “Cautionary Statement Regarding Forward-Looking Statements” on page 29 of this Quarterly Report on Form 10-Q.

Unless otherwise indicated by the context, all references in this Quarterly Report on Form 10-Q to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Similarly, references to a year (e.g., 2027) refer to our fiscal year ended March 31 of that year.

General

We are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter ("OTC") health and personal care products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.  We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage.

We have grown our brand portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of consumer health and personal care brands have also been an important part of our growth strategy. We have acquired well-recognized brands from consumer products and pharmaceutical companies and private equity firms. While many of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, most were considered “non-core” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a core brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network.  We pursue this growth through increased spending on advertising and marketing support, new sales and marketing strategies, improved packaging and formulations, and innovative development of brand extensions.

Acquisitions

Acquisition of the OTC Wellness Business

On June 12, 2026, we completed the acquisition of Breathe Right and certain other brands (the "OTC Wellness Business"), from Foundation Consumer Brands, LLC and certain of its affiliates for a purchase price of $1,045.0 million in cash (the "Breathe Right Acquisition"). In connection with this acquisition, we entered into a Term Loan Credit Agreement on June 12, 2026 (the "Term Loan Credit Agreement") providing for term loans in the amount of $1,045.0 million, the proceeds of which were used to, along with cash on hand, finance the Breathe Right Acquisition and fees and expenses incurred in connection with the closing of the Term Loan Credit Agreement and the Breathe Right Acquisition. As a result of this acquisition, we acquired certain assets primarily related to a portfolio of over-the-counter consumer health products.

The results of the OTC Wellness Business have been included in our consolidated financial statements from the acquisition date. Unaudited pro forma financial information giving effect to the acquisition as if it had occurred at the beginning of fiscal 2026 is included in Note 2., Acquisitions.

Acquisition of Pillar5

On December 18, 2025, we completed the acquisition of Pillar5 Pharma, Inc. ("Pillar5"), which was funded through a combination of cash on hand and our existing asset-based revolving credit facility.

Based in Ontario, Canada, Pillar5 is a leading sterile ophthalmic manufacturer and one of our current Clear Eyes suppliers.

The pro-forma effect of this acquisition on revenues and earnings was not material.

22

The details of the OTC Wellness Business and Pillar5 acquisitions are included in the notes to the unaudited Condensed Consolidated Financial Statements in Part I, Item I, Note 2., Acquisitions, of this Quarterly Report on Form 10-Q.

Economic Environment

There has been economic uncertainty in the United States and globally due to several factors, including evolving fiscal policy, global supply chain constraints, changes in interest rates, a high inflationary environment, geopolitical events and evolving U.S. and international trade restrictions and tariffs. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a shift in many markets to purchasing our products online, and have and may continue to see changes in retailer purchasing patterns due to these consumer patterns and the uncertain economic environment.

The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. We have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results of operations and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including global supply chain constraints, inflation, tariffs, global conflicts and trade actions/disputes. These effects could have a material adverse impact on our business, liquidity, capital resources and results of operations and those of the third parties on which we rely.

Manufacturing

Certain of our third-party manufacturers have experienced, and may continue to experience, difficulty meeting demand, which has contributed to shortages of certain products, particularly sterile eye care products, as a result of manufacturing improvement initiatives, heightened regulatory scrutiny and evolving regulatory expectations. Recently, all of our sterile eye care manufacturing sites, including those operated by certain third-party manufacturers, have undergone inspections by health authorities, and we and our third-party manufacturers are actively engaging with those authorities and implementing responsive actions intended to strengthen quality systems, improve production consistency and support more reliable supply over time. These activities may result in periods of manufacturing variability, reduced capacity, production delays or product shortages if related remediation, qualification, validation or regulatory readiness activities take longer than expected. These shortages have negatively impacted our results of operations, and further shortages may continue to have a negative impact on sales of our eye care products. We believe these ongoing investments and engagement with health authorities will better position us and our third-party manufacturers to improve supply reliability and support recovery in affected product categories over the long-term.

Income Taxes

Numerous countries have agreed to a statement in support of the Organization for Economic Cooperation and Development ("OECD") model rules that propose a global minimum tax rate of 15%. Certain countries have enacted, or are in the process of enacting, legislation to address the global minimum tax. This legislation has not and is not expected to have a material impact on our Consolidated Financial Statements. As legislation becomes effective in more countries in which we do business, our taxes could increase and negatively impact our provision for income taxes. We continue to monitor pending legislation and implementation by countries and to evaluate the potential impact on our business in future periods.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The OBBBA makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. We evaluated the provisions of the OBBBA and determined that there was no material impact on our estimated annual effective tax rate.

23

Results of Operations

Three Months Ended June 30, 2026 compared to the Three Months Ended June 30, 2025

Total Segment Revenues

In connection with the acquisition of the OTC Wellness Business, the Company established a new product category, Wellness, Sleep & Other, and renamed certain existing product categories. As a result, certain brands were reclassified among product categories. Prior period amounts have been reclassified to conform to the current period presentation.

The following table represents total revenue by segment, including product groups, for the three months ended June 30, 2026 and 2025.

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1295947/000129594726000016/pbh-20260331.htm
Complete FY 2026 MD&A: /company/PBH/mda/fy2026/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-05-14
Report date: 2026-03-31

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with the Consolidated Financial Statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties that could cause actual results to differ materially from those implied or described by the forward-looking statements. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A. “Risk Factors” in this Annual Report on Form 10-K, as well as those described in future reports filed with the SEC.

General

We are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name OTC health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.  We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to create our competitive advantage.

We have grown our product portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of consumer health and personal care brands have also been an important part of our growth strategy. We have acquired well-recognized brands from consumer products and pharmaceutical companies and private equity firms. While certain of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, many were considered “non-strategic” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network. We pursue this growth through increased spending on advertising and marketing support, new sales and marketing strategies, improved packaging and formulations and innovative development of brand extensions.

Acquisitions

Acquisition of Pillar5

On December 18, 2025, we completed the acquisition of Pillar5, which was funded through a combination of cash on hand and our existing asset-based revolving credit facility.

Based in Arnprior Ontario, Canada, Pillar5 is a leading sterile ophthalmic manufacturer and one of our current Clear Eyes suppliers.

The pro-forma effect of this acquisition on revenues and earnings was not material.

The details of this acquisition are included in the notes to the Consolidated Financial Statements in Part II, Item 8, Note 2 of this Annual Report on Form 10-K.

Pending Acquisition of Foundation Consumer Brands Product Portfolio

On March 19, 2026, we entered into a definitive agreement to acquire certain assets and assume certain liabilities primarily related to a portfolio of over-the-counter consumer health products, including Breathe Right® and certain other brands from Foundation Consumer Brands, LLC. We anticipate the transaction to close in the first half of fiscal 2027.

Economic Environment

There has been economic uncertainty in the United States and globally due to several factors, including evolving fiscal policy, global supply chain constraints, changes in interest rates, a high inflationary environment, geopolitical events, including conflicts in the Middle East, and evolving U.S. and international trade restrictions and tariffs. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a shift in many markets to purchasing our products online, and have and may continue to see changes in retailer purchasing patterns due to these consumer patterns and the volatile economic environment.

34

The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. We have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. We and our manufacturers are currently having, and have had in the past, difficulty meeting demand, which is and has caused shortages of some of our products, particularly eye care products. These shortages have negatively impacted our results of operations, and we expect further shortages will continue to have a negative impact on our sales. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results of operations and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including global supply chain constraints, inflation, tariffs, global conflicts and trade actions/disputes. These effects could have a material adverse impact on our business, liquidity, capital resources and results of operations and those of the third parties on which we rely.

Critical Accounting Estimates

Our significant accounting policies are described in the notes to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.  While all significant accounting policies are important to our Consolidated Financial Statements, certain of these policies may be viewed as being critical.  Such policies are those that are both most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses or the related disclosure of contingent assets and liabilities.  These estimates are based on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances.  Actual results may differ materially from these estimates. The following are our most critical accounting estimates:

Revenue Recognition, Customer Programs and Variable Consideration

Revenue is recognized when control of a promised good is transferred to a customer, in an amount that reflects the consideration that we expect to be entitled to receive in exchange for that good. This occurs either when finished goods are transferred to a common carrier for delivery to the customer or when product is picked up by the customer or the customer’s carrier.

Once a product has transferred to the common carrier or been picked up by the customer, the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the product. It is at this point that we have a right to payment and the customer has legal title.

Provisions for certain rebates, customer promotional programs, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales.

We record an estimate of future product returns, chargebacks and logistics deductions concurrent with recording sales, which is made using the most likely amount method that incorporates (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings and (vi) the impact of changes in product formulation, packaging and advertising.

We participate in the promotional programs of our customers to enhance the sale of our products. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution including slotting fees, and cooperative advertising. The costs of such activities are recorded as a reduction to revenue when the related sale takes place. Estimates of the costs of these promotional programs are derived using the most likely amount method, which incorporates (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Goodwill and Intangible Assets

At March 31, 2026 and 2025, goodwill and intangible assets were apportioned among similar product groups within our operating segments as follows:

35

[[GREPCENT_TABLE]]
[["","March 31, 2026"],["(In thousands)","North American OTC Healthcare","","International OTC Healthcare","","","","Consolidated"],["Goodwill","$","550,987","","","$","30,122","","","","","$","581,109"],["Intangible assets"],["Indefinite-lived","2,068,752","","","74,923","","","","","2,143,675"],["Finite-lived","138,903","","","17,027","","","","","155,930"],["Intangible assets, net","2,207,655","","","91,950","","","","","2,299,605"],["Total","$","2,758,642","","","$","122,072","","","","","$","2,880,714"]]
[[/GREPCENT_TABLE]]

[[GREPCENT_TABLE]]
[["","March 31, 2025"],["(In thousands)","North American OTC Healthcare","","International OTC Healthcare","","","","Consolidated"],["Goodwill","$","498,936","","","$","28,489","","","","","$","527,425"],["Intangible assets"],["Indefinite-lived","2,068,752","","","68,234","","","","","2,136,986"],["Finite-lived","141,234","","","17,130","","","","","158,364"],["Intangible assets, net","2,209,986","","","85,364","","","","","2,295,350"],["Total","$","2,708,922","","","$","113,853","","","","","$","2,822,775"]]
[[/GREPCENT_TABLE]]

At March 31, 2026, the brands with the highest carrying value were Monistat, BC/Goody's, Summer's Eve, TheraTears and Fleet, comprising approximately 59% of our total intangible assets value.

Goodwill and intangible assets comprise the majority of all of our assets.  Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination.  Intangible assets generally represent our tradenames, brand names and patents.  When we acquire a brand, we are required to make judgments regarding the value assigned to the associated intangible assets, as well as their respective useful lives.  Management considers many factors both prior to and after the acquisition of an intangible asset in determining the value, as well as the useful life, assigned to each intangible asset that we acquire or continue to own and promote.

The most significant factors are:

•Brand History

A brand that has been in existence for a long period of time (e.g., 25, 50 or 100 years) generally warrants a higher valuation and longer life (sometimes indefinite) than a brand that has been in existence for a very short period of time.  A brand that has been in existence for an extended period of time generally has been the subject of considerable investment by its previous owner(s) to support product innovation and advertising and marketing.

•Market Position

Consumer products that rank number one or two in their respective market generally have greater name recognition and are known as quali

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2026 MD&A: /company/PBH/mda/fy2026/
All MD&A years: /company/PBH/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2025 MD&A](/company/PBH/mda/fy2025/): filed 2025-05-09; accession 0001295947-25-000017 (https://www.sec.gov/Archives/edgar/data/1295947/000129594725000017/pbh-20250331.htm)
- [FY 2024 MD&A](/company/PBH/mda/fy2024/): filed 2024-05-15; accession 0001295947-24-000017 (https://www.sec.gov/Archives/edgar/data/1295947/000129594724000017/pbh-20240331.htm)
- [FY 2023 MD&A](/company/PBH/mda/fy2023/): filed 2023-05-05; accession 0001295947-23-000017 (https://www.sec.gov/Archives/edgar/data/1295947/000129594723000017/pbh-20230331.htm)
- [FY 2022 MD&A](/company/PBH/mda/fy2022/): filed 2022-05-06; accession 0001295947-22-000015 (https://www.sec.gov/Archives/edgar/data/1295947/000129594722000015/pbh-20220331.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2834 Pharmaceutical Preparations) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/PBH.md · JSON record: /company/PBH.json · verified financials: /company/PBH/financials.json / /company/PBH/financials.csv · machine TOC for the whole site: /llms.txt